A Phase I study of the anti-KIR antibody IPH2102/BMS-986015 in combination with ipilimumab in patients with selected advanced solid tumors published on ClinicalTrials.gov Innate Pharma SA (the...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the first...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, updates on four early clinical...

Revenue of 8.0 million euros Cash position as at September 30, 2012 of 32.3 million euros Change to the supervisory board Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces its second participation to...

A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the...

23 patients, median age 71, in first complete remission, received escalating doses of IPH2101 Conclusions support the rationale behind the recently announced multicentre, double-blind, Phase II trial...

Three-year cash horizon resulting from collaboration and licensing agreement with Bristol-Myers Squibb Significant advance of the IPH21 program with the regulatory authorization to start the first...

First randomized Phase II trial of the anti-KIR antibody IPH2102 Led by French Cooperative Groups in AML and sponsored by Innate Pharma Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 –...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that its Annual General Meeting (“AGM”) took place on June 28, 2012, in Marseilles, France. A number of 21,148,778 votes were expressed out...